Anticoagulant Treatment is Associated with Decreased Mortality in Severe Coronavirus Disease 2019 Patients with Coagulopathy

Overview

Journal J Thromb Haemost

Publisher Elsevier

Specialty Hematology

Date 2020 Mar 29

PMID 32220112

Citations 2028

Authors

Ning Tang

Huan Bai

Xing Chen

Jiale Gong

Dengju Li

Ziyong Sun

Affiliations

Soon will be listed here.

Abstract

Background: A relatively high mortality of severe coronavirus disease 2019 (COVID-19) is worrying, and the application of heparin in COVID-19 has been recommended by some expert consensus because of the risk of disseminated intravascular coagulation and venous thromboembolism. However, its efficacy remains to be validated.

Methods: Coagulation results, medications, and outcomes of consecutive patients being classified as having severe COVID-19 in Tongji hospital were retrospectively analyzed. The 28-day mortality between heparin users and nonusers were compared, as was a different risk of coagulopathy, which was stratified by the sepsis-induced coagulopathy (SIC) score or D-dimer result.

Results: There were 449 patients with severe COVID-19 enrolled into the study, 99 of them received heparin (mainly with low molecular weight heparin) for 7 days or longer. D-dimer, prothrombin time, and age were positively, and platelet count was negatively, correlated with 28-day mortality in multivariate analysis. No difference in 28-day mortality was found between heparin users and nonusers (30.3% vs 29.7%, P = .910). But the 28-day mortality of heparin users was lower than nonusers in patients with SIC score ≥4 (40.0% vs 64.2%, P = .029), or D-dimer >6-fold of upper limit of normal (32.8% vs 52.4%, P = .017).

Conclusions: Anticoagulant therapy mainly with low molecular weight heparin appears to be associated with better prognosis in severe COVID-19 patients meeting SIC criteria or with markedly elevated D-dimer.

Citing Articles

The Impact of SARS-CoV-2 Infection on Glucose Homeostasis in Hospitalized Patients with Pulmonary Impairment.

Parliteanu O, Balteanu M, Zaharia D, Constantinescu T, Cristea A, Dumitrache-Rujinscki S Diagnostics (Basel). 2025; 15(5).

PMID: 40075801 PMC: 11898410. DOI: 10.3390/diagnostics15050554.

Harnessing Epigenetics: Innovative Approaches in Diagnosing and Combating Viral Acute Respiratory Infections.

Saha A, Ganguly A, Kumar A, Srivastava N, Pathak R Pathogens. 2025; 14(2).

PMID: 40005506 PMC: 11858160. DOI: 10.3390/pathogens14020129.

Genetic and Epigenetic Intersections in COVID-19-Associated Cardiovascular Disease: Emerging Insights and Future Directions.

Sabit H, Arneth B, Altrawy A, Ghazy A, Abdelazeem R, Adel A Biomedicines. 2025; 13(2).

PMID: 40002898 PMC: 11852909. DOI: 10.3390/biomedicines13020485.

Can nebulised heparin reduce acute lung injury in patients with SARS‑CoV‑2 requiring advanced respiratory support in Ireland: the CHARTER‑Ireland phase Ib/IIa, randomised, parallel-group, open-label study.

Cosgrave D, McNicholas B, Hanley C, Sheehan J, Calpin P, Kernan M Intensive Care Med Exp. 2025; 13(1):15.

PMID: 39920521 PMC: 11806160. DOI: 10.1186/s40635-025-00727-x.

Peculiarities of in-Stent Thrombosis and Restenosis in Coronary Arteries Post-COVID-19: A Systematic Review of Clinical Cases and Case Series.

Pivina L, Batenova G, Omarov N, Ygiyeva D, Messova A, Alibayeva G Open Access Emerg Med. 2025; 17:15-30.

PMID: 39872756 PMC: 11769847. DOI: 10.2147/OAEM.S470523.

References

Schmitt F, Manolov V, Morgenstern J, Fleming T, Heitmeier S, Uhle F . Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study. Ann Intensive Care. 2019; 9(1):19. PMC: 6353981. DOI: 10.1186/s13613-019-0499-6. View

Dong L, Hu S, Gao J . Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020; 14(1):58-60. DOI: 10.5582/ddt.2020.01012. View

Singer M, Deutschman C, Seymour C, Shankar-Hari M, Annane D, Bauer M . The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8):801-10. PMC: 4968574. DOI: 10.1001/jama.2016.0287. View

Stein P, Kayali F, Olson R, Milford C . Pulmonary thromboembolism in Asians/Pacific Islanders in the United States: analysis of data from the National Hospital Discharge Survey and the United States Bureau of the Census. Am J Med. 2004; 116(7):435-42. DOI: 10.1016/j.amjmed.2003.11.020. View

Tang N, Li D, Wang X, Sun Z . Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18(4):844-847. PMC: 7166509. DOI: 10.1111/jth.14768. View

Gupta N, Zhao Y, Evans C . The stimulation of thrombosis by hypoxia. Thromb Res. 2019; 181:77-83. DOI: 10.1016/j.thromres.2019.07.013. View

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506. PMC: 7159299. DOI: 10.1016/S0140-6736(20)30183-5. View

Sun H, Wang X, Degen J, Ginsburg D . Reduced thrombin generation increases host susceptibility to group A streptococcal infection. Blood. 2008; 113(6):1358-64. PMC: 2637198. DOI: 10.1182/blood-2008-07-170506. View

Liu X, Wang X, Liu X, Hao D, Jaladat Y, Lu F . Low-dose heparin as treatment for early disseminated intravascular coagulation during sepsis: A prospective clinical study. Exp Ther Med. 2014; 7(3):604-608. PMC: 3919907. DOI: 10.3892/etm.2013.1466. View

10.

Iba T, Levy J, Warkentin T, Thachil J, van der Poll T, Levi M . Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost. 2019; 17(11):1989-1994. DOI: 10.1111/jth.14578. View

11.

Iba T, Di Nisio M, Levy J, Kitamura N, Thachil J . New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open. 2017; 7(9):e017046. PMC: 5623518. DOI: 10.1136/bmjopen-2017-017046. View

12.

Iba T, Gando S, Thachil J . Anticoagulant therapy for sepsis-associated disseminated intravascular coagulation: the view from Japan. J Thromb Haemost. 2014; 12(7):1010-9. DOI: 10.1111/jth.12596. View

13.

Menter D, Kopetz S, Hawk E, Sood A, Loree J, Gresele P . Platelet "first responders" in wound response, cancer, and metastasis. Cancer Metastasis Rev. 2017; 36(2):199-213. PMC: 5709140. DOI: 10.1007/s10555-017-9682-0. View

14.

Venclauskas L, Llau J, Jenny J, Kjaersgaard-Andersen P, Jans O . European guidelines on perioperative venous thromboembolism prophylaxis: Day surgery and fast-track surgery. Eur J Anaesthesiol. 2017; 35(2):134-138. DOI: 10.1097/EJA.0000000000000706. View

15.

Zakai N, McClure L . Racial differences in venous thromboembolism. J Thromb Haemost. 2011; 9(10):1877-82. DOI: 10.1111/j.1538-7836.2011.04443.x. View

16.

Nishida O, Ogura H, Egi M, Fujishima S, Hayashi Y, Iba T . The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J-SSCG 2016). Acute Med Surg. 2018; 5(1):3-89. PMC: 5797842. DOI: 10.1002/ams2.322. View

17.

Levi M, van der Poll T . Coagulation and sepsis. Thromb Res. 2016; 149:38-44. DOI: 10.1016/j.thromres.2016.11.007. View

18.

Vincent J, Moreno R, Takala J, Willatts S, de Mendonca A, Bruining H . The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996; 22(7):707-10. DOI: 10.1007/BF01709751. View

19.

Umemura Y, Yamakawa K, Ogura H, Yuhara H, Fujimi S . Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials. J Thromb Haemost. 2015; 14(3):518-30. DOI: 10.1111/jth.13230. View

20.

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y . Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223):507-513. PMC: 7135076. DOI: 10.1016/S0140-6736(20)30211-7. View